NICE provisionally rejects Ipsen’s kidney cancer drug Cabometyx

pharmafile | February 21, 2017 | News story | Manufacturing and Production, Sales and Marketing Cometriq, NICE, ipsen 

NICE has announced draft guidance for Ipsen’s cancer drug Cabometyx (cabozantinib), revealing it does not recommend the drug for use on the NHS for the treatment of advanced renal cell carcinoma in patients who have undergone previous therapy.

The institute’s committee could not agree that the drug was a cost-effective use of NHS resources, with each Quality Adjusted Life Year coming to a total exceeding £30,000 compared to similar offerings. It also came to the decision that the submission supplied by Ipsen was not robust enough to support the drug’s efficacy over comparable treatments.

Cabometyx is a multiple receptor tyrosine kinase inhibitor; Ipsen secured exclusive commercialisation and development rights to the drug in regions outside of the US, Canada and Japan in February 2016.

The draft guidance is now open for public consultation until 14 March.

Matt Fellows

Related Content

Novo Nordisk launches Wegovy in the UK

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK …

Amicus Therapeutics’ Pompe disease treatment approved for use in UK

Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the …

FDA approved Ipsen’s Sohonos capsules for treatment of fibrodysplasia ossificans progressiva

Ipsen has announced that the US Food and Drug Administration (FDA) has approved Sohonos (palovarotene) …

Latest content